培美曲赛联合顺铂二线治疗晚期肺腺癌临床分析  

Clinical observation of pemetrexed pombined cisplaton as second-line treatment for advanced lung adenocarcinoma

作　　者：李会枚[1] 余海清[1] 庞世权[1] 

机构地区：[1]广东医学院附属西乡人民医院健诊科,广东深圳518000

出　　处：《海南医学》2011年第12期82-83,共2页Hainan Medical Journal

基　　金：深圳市宝安区科技计划项目(编号:2010595)

摘　　要：目的探讨培美曲赛联合顺铂方案治疗一线吉非替尼治疗失败的晚期肺腺癌的临床疗效和毒性。方法对2009年1月至2010年6月本院60例一线应用吉非替尼与卡铂/紫杉醇（CP方案）化疗失败的晚期肺腺癌患者使用培美曲赛联合顺铂方案化疗。化疗方法：培美曲赛500mg/m2加入生理盐水（0.9%氯化钠注射液）100ml静脉点滴;顺铂75mg/m2,分3~5d,每3周重复一次,完成2个周期以上化疗评价临床疗效和毒性。结果①60例患者中,完全缓解（CR）0例,部分缓解（PR）4例,稳定（SD）35例,进展（PD）21例,总有效率为6.7%（4/60）,疾病控制率（DCR）为65.0%（39/60）。②毒性反应主要是疲乏无力33例（55.0%）,白细胞下降26例（43.3%）,Ⅲ度下降4例（6.7%）,胃肠道反应19例（31.7%）,过敏反应2例（3.3%）,经对症处理后不影响化疗。结论培美曲赛联合顺铂方案是一线治疗失败的晚期肺腺癌的理想方案之一。Objective To explore the efficacy and toxicity of pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma.Methods 60 cases with end-stage lung adenocarcinoma who were failed treatment for nehemiah and carboplatin/taxol（CP） chemotherapy were used pemetrexed combined cisplaton AS chemotherapy from January 2009 to June 2010 in our hospital.100 ml of pemetrexed 500 mg/m2 joining 0.9% of sodium chloride were for intravenous injection,cisplatin 75 mg/m2,repeat one time each 3 weeks,completed two cycles about above chemotherapy and evaluated the clinical and toxicity.Results 1） Complete remission（CR） was 0 case,partial remission（PR） were 4 cases,stable（SD） were 35 cases and progress（PD） were 11 cases in 60 patients;the total effective was 6.7%（4/60）,the rates of disease control（DCR） was 65.0%（39/60）.（2） Toxicity is mainly exhaustion of 33 cases（55.0%）,leukocyte fell were 26 cases（43.3%）,degrees decline were 4 cases（6.7%）,gastrointestinal reaction were 19 cases（31.7%）,allergic reactions were 2 cases（3.3%）,it did not affect chemotherapy after symptomatic treatment.Conclusion Pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma is one of the ideal solutions.

关 键 词：培美曲赛 顺铂 晚期肺腺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]